SBIR Phase I: Improved COVID-19 Testing by Rapid Sample Purification

这项小企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力是提高冠状病毒检测的可靠性。拟议的项目将开发一种组织纯化技术，从患者样本中提取（纯化）病毒。更纯净的样本（更多的冠状病毒，更少的混淆材料）预计将改善病毒的信号，减少非病毒材料的信号，因此预计将提高检测的可靠性（减少假阳性和假阴性）。这可能会影响到大流行的社会距离。这是小企业创新研究（SBIR）的第一阶段项目，该系统用于提取纯化样品，用于冠状病毒检测，用于下游检测，如基于pcr的分析。该系统是一种新型纯化技术，使用生物（抗体）和其他物理方法快速可靠地从人体样本中提取目标微生物（这里是COVID病毒）。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an improved reliability for coronavirus detection. The proposed project will develop a tissue purification technology to extract (purify) virus from patient samples. Purer samples (more coronavirus, less confounding materials) is anticipated to improve signal from virus and reduce signal from non-virus materials, and is therefore anticipated to improve the reliability of testing (fewer false positives and false negatives). This can potentially impact the social distancing of the pandemic. This Small Business Innovation Research (SBIR) Phase I project of a system to extract purified samples for coronavirus testing for downstream testing, such as PCR-based analysis. The system is a novel purification technology that uses biological (antibodies) and other physical to quickly and reliably extract target microorganisms (here COVID viruses) from human samples.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.